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Abstract
Mice lacking the 4th-group paralog Hoxd4 display malformations of the anterior vertebral column, but are viable and fertile.
Here, we report that zebrafish embryos having decreased function of the orthologous hoxd4a gene manifest striking
perturbations in vasculogenesis, angiogenesis and primitive and definitive hematopoiesis. These defects are preceded by
reduced expression of the hemangioblast markers scl1, lmo2 and fli1 within the posterior lateral plate mesoderm (PLM) at 13
hours post fertilization (hpf). Epistasis analysis revealed that hoxd4a acts upstream of meis1.1 but downstream of cdx4 as
early as the shield stage in ventral-most mesoderm fated to give rise to hemangioblasts, leading us to propose that loss of
hoxd4a function disrupts hemangioblast specification. These findings place hoxd4a high in a genetic hierarchy directing
hemangioblast formation downstream of cdx1/cdx4 and upstream of meis1.1. An additional consequence of impaired
hoxd4a and meis1.1 expression is the deregulation of multiple Hox genes implicated in vasculogenesis and hematopoiesis
which may further contribute to the defects described here. Our results add to evidence implicating key roles for Hox genes
in their initial phase of expression early in gastrulation.
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Introduction
The processes of vasculogenesis, angiogenesis and hematopoi-
esis establish the circulatory system and blood lineages of the
embryo [1–4]. In zebrafish, the precursors of the vascular and
hematopoietic systems derive from unipotential progenitors as well
as a common progenitor known as the hemangioblast [5]. The
hemangioblast is identifiable by the expression of the scl gene
within the PLM [1,3]. The first blood vessels are laid down
through the process of vasculogenesis whereby angioblasts under
the influence of vascular endothelial growth factor (VEGF) migrate
and then aggregate as endothelial cells to form a vascular cord [2].
Subsidiary blood vessels are then formed by sprouting from
existing vessels in a process termed angiogenesis [2].
In zebrafish, markers of vasculogenesis are apparent at 12 hpf
with the formation of scl1-expressing cells in the anterior lateral
plate mesoderm (ALM) and scl- and fli1-expressing angioblasts in
the PLM [2,3]. Between 18 and 22 hpf, angioblasts migrate to the
midline, merge and lumenize to form the primary blood vessel [2].
Recent evidence suggests that the second major axial vessel, the
posterior cardinal vein (PCV) is produced from the ventral side of
the primary vessel through a process of ventral sprouting between
21 and 24 hpf; it expresses ephb4a and is distinguished from the
dorsal aorta (DA) which expresses the arterial marker efnb2a [2].
From 20 hpf, new vessels sprout from the preexisting DA and at
32 hpf from the PCV [2]. From the DA, the primary interseg-
mental vessels (ISV) sprout dorsally, followed by the secondary
ISV from PCV [2].
As in other vertebrates, blood development in zebrafish initiates
with primitive hematopoiesis and is then followed by definitive
hematopoiesis which establishes the adult blood lineages [1,3]. In
mammals and birds, the extra-embryonic yolk sac is the primary
site of hematopoiesis, while in zebrafish markers of primitive
hematopoiesis are apparent at 10 to 11 hpf (2 somite stage) in the
ALM and PLM as revealed by the expression of hemangioblast
markers scl1 and lmo2 [1,3]. The first signs of commitment to
primitive hematopoiesis are given by the expression of gata1 in a
subset of scl1 positive cells of the PLM [1]. The myeloid
progenitors and some endothelial cells are produced in the
ALM. By 14 hpf (10 somite stage), precursors in the PLM
commence migration to the midline and there form the
intermediate cell mass (ICM), the major site of primitive
hematopoiesis in the posterior of the embryo [1,3]. Circulation
initiates at 24 hpf following which a transient site of erythromye-
lopoiesis, the posterior blood island (PBI), functions over the next
12 hours [4].
The second and definitive wave of hematopoiesis begins in the
ventral wall of the DA at 24 hpf [1,3]. The ventral DA is
considered to be the counterpart of the aorta-gonad-mesonephros
(AGM) region of amniotes. HSCs arise in the AGM beginning at
24 hpf and are identifiable by expression of runx1 and cmyb.
Starting at 48 hpf, the HSCs then seed what will become the
hematopoietic stroma of the caudal hematopoietic tissue (CHT) at
3 dpf, followed by expansion and differentiation [4,6]. The CHT,
which assumes the role of the fetal liver in mammals, is responsible
for definitive hematopoiesis until the kidney marrow becomes the
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final hematopoietic site beginning at 4 days post-fertilization (dpf).
The kidney marrow and the thymus become the lifelong primary
hematopoietic sites in larval and adult life [1,3].
Several genes have been implicated in the control of successive
steps in the formation of blood and the vasculature. In zebrafish,
the earliest acting gene to be identified to date is cloche [7] which
may be synonymous with the acyltransferase-encoding gene lycat
[8]. Also very high in the genetic hierarchy governing vasculo-
genesis and hematopoiesis are cdx1 and cdx4 [9,10]. The severe
hematopoietic defects seen in zebrafish cdx4 single mutants and
cdx1/cdx4 doubly deficient embryos are accompanied by the
down-regulation of the hemangioblast and hematopoietic stem cell
(HSC) marker scl1 and a number of Hox genes, and normal
hematopoiesis can be rescued by the forced expression of hoxa9a
[10].
Hox genes have also been implicated in hematopoietic and
vasculogenic processes in mammals [11–13]. Their protein
products are characterized by a conserved DNA-binding homeo-
domain and bind DNA cooperatively with members of the TALE
homeoprotein family of cofactors [14] such as MEIS (Myeloid
Ecotropic Integration Site), PBX (Pre-B-Cell Leukemia Homeo-
box), and PREP/PKNOX (Pbx Knotted Homeobox). There are
39 Hox genes in human and mouse organized into four clusters
[15]. Extensive evidence implicates both Hox gene products and
their cofactors in hematopoietic function [14,16–21]. The ablation
of any of several murine Hox genes, including Hoxb4, leads to
defects in blood lineages. Hoxb4 and indeed all remaining Hox
genes of paralog group 4 (Hoxa4, Hoxc4, Hoxd4) display potent
HSC-promoting functions [13,22]. Similar activities are shared by
the murine HOX cofactors PREP1, MEIS1 and PBX1 as revealed
by hematopoietic and cardiac deficiencies in corresponding
mutant animals [14,21,23–27]. The natural role for Hox and
Meis1 genes in normal hematopoiesis is further reflected in their
well-documented contributions to human and murine leukemias
[13,28–31].
In teleosts, a genome duplication event generated 8 Hox clusters,
with zebrafish retaining 7 clusters and 47 genes following
evolutionary loss [32]. In zebrafish, hoxb6b, hoxb7a, and hoxa9a
are known to regulate primitive hematopoiesis and are required
for hematopoietic stem cell formation [9,10], while deficiencies in
pbx and meis function strongly compromise primitive and definitive
hematopoiesis as well as the vasculature [18–20] pointing to a
conservation of function across vertebrates.
Mice lacking Hoxd4 function show abnormalities of the anterior-
most vertebrae, the atlas and axis, but are viable and fertile
[33,34]. We explored the extent to which function was conserved
in zebrafish by assessing the phenotype of hoxd4a loss-of-function
morphants. We demonstrate a surprising role for zebrafish hoxd4a
in vasculogenesis, angiogenesis and primitive and definitive
hematopoiesis. Defects resulting from hoxd4a deficiency can be
rescued by capped mRNA for hoxd4a, meis1.1, scl, and fli1 but not
by cdx4. Impaired meis1.1 function following hoxd4a knockdown
leads to widespread Hox gene deregulation including the reduced
expression of Hox genes previously implicated in hematopoiesis,
vasculogenesis and angiogenesis. The cdx4, hoxd4a and meis1.1
genes are spatially and temporally co-expressed in shield-stage
embryos within the ventral-most presumptive mesoderm, the site
from which fate mapping studies have shown the hemangioblast to
arise [5,35,36]. Moreover, shield-stage hoxd4a morphants display
decreased meis1.1 expression in ventral-most presumptive meso-
derm, and this meis1.1 expression is rescued by prior injection of
capped hoxd4a mRNA. Thus, our data indicate that hoxd4a
functions at the earliest times and near the top of a regulatory
hierarchy directing hemangioblast formation, acting downstream
or in parallel to cdx genes, but upstream or parallel to meis1.1.
Another consequence of impaired hoxd4a and meis1.1 function is
the subsequent deregulation of multiple Hox genes previously
implicated in vasculogenic and hematopoietic processes. We
conclude that hoxd4a has acquired (or retained) a much more
important role in hematopoiesis and vasculogenesis than observed
for its murine ortholog Hoxd4. Additionally, our results add to a
growing body of evidence defining functions for Hox genes during
their early phase of expression at gastrulation, well before they are
deployed along the antero-posterior axis proper.
Methods
Ethics Statement
All animal work conformed to the Institutional Animal Care
and Use Committee (IACUC) guidelines at Nanyang Technolog-
ical University and was reviewed and approved under protocol
number ARF SBS/NIE-A 0144 AZ.
Zebrafish
Wild-type AB and transgenic (fli1:EGFP) [37] and Tg(ga-
ta1:dsRed) [38] lines of zebrafish were maintained as described
[39]. Zebrafish embryos were staged as detailed previously [40].
Antisense Morpholino and mRNA Microinjection
Antisense morpholino oligonucleotides (MOs) were obtained
from Gene Tools Inc and injected into zebrafish embryos at 1–4
cell stage. Splice MOs targeting the 59 splice site intron-exon
junction (splice acceptor) are designated as follows MO1:59-GTT
CAC TGT GAA GGA CAA AAT CAC A-39 and exon-intron
junction (splice donor), MO2:59- GCA AAG AGA GTG GAT
CTT ACC CGT A-39. MOs were diluted in Danieau’s buffer
(0.4 mM MgSO4, 0.6 mM CaCl2, 0.7 mM KCl, 58 mM NaCl,
and 5 mM Hepes, pH 7.6). Optimal doses for each MO were
tested based on phenotypic effects, and each experiment was
performed in parallel with a non-specific MO (standard control
MO supplied by GeneTools Inc) injected at the same concentra-
tion.
Full-length cDNA for hoxd4a was generated by PCR using the
primers shown in Table S1 in File S1 and cloned into pCRHII-
TOPOH. The mMESSAGE mMACHINE Kit (Ambion) was used
to synthesize capped mRNA. All mRNAs used for rescue
experiments were assessed over a range of concentrations and
the following amounts were chosen as the minimum sufficient to
induce rescue: scl1 (100 pg), fli1a (30 pg), meis1.1 (100 pg) and
hoxd4a (50 pg). All injections were done at the 1-cell stage.
qRT-PCR
Total RNA was extracted from embryos at 26–28 hpf using the
PureLinkTM Micro-to-MidiTM Total RNA Purification System
(Invitrogen). 1 mg total RNA was treated with 1 U DNase I
(Fermentas) at 37uC for 15 min and used for reverse transcription
with SuperScriptH III First-Strand Synthesis (Invitrogen). Quan-
titative reverse transcriptase PCR (qRT-PCR) was performed
using SYBR GreenERTM qPCR SuperMix (Invitrogen) on a
BioRad iCycler iQ5. The data (in biological triplicates) were
normalized against zebrafish b-actin. The sequences of the
oligonucleotides used for qRT-PCR are given in Table S2 in
File S1.
Whole Mount in situ Hybridization and Imaging
Whole mount in situ hybridization (WISH) was performed as
previously described [41]. For nkx2.5, a PCR fragment was
amplified from 26–28 hpf embryonic cDNA using the primers
hoxd4a in Hematopoiesis and Vasculogenesis
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shown in Table S1 in File S1. The reverse primer incorporated
a T7 promoter allowing the PCR product to be used directly for
probe production. DIG- labeled antisense RNA probes were
transcribed from linearized template using T3, T7 or SP6 RNA
polymerase (Roche). Probes for hoxb6b and hoxb7a were derived by
RT-PCR-mediated amplification from RNA from 26–28 hpf
embryos using primers described in Wan et al [42]. Embryos
were incubated with anti-DIG antibody (Roche) and probes were
detected using NBT/BCIP (nitro blue tetrazolium chloride/5-
bromo-4-chloro-3-indolyl phosphate, toluidine salt) from Roche.
Images were obtained on a Zeiss lumar V.12 stereo microscope
with an Axio Cam MRc (Zeiss) and Axio Vision software. Some
embryos were then dissected away from the yolk and flat-mounted
prior to photography.
Alkaline Phosphatase Staining of Blood Vessels
Embryos at 72 hpf were fixed with 4% paraformaldehyde in
PBS (phosphate buffered saline) at room temperature for 30 min,
followed by treatment with pre-cooled acetone for 30 min at
220uC. After rinsing with PBS twice (5 min each), the embryos
were equilibrated with NTMT buffer (100 mM Tris pH 9.5,
50 mM MgCl2, 100 mM NaCl, 0.1% Tween 20) for three times
(each for 15 min) at room temperature. For alkaline phosphatase
staining, the embryos were incubated in NBT/BCIP (Roche)
solution for 30 min.
O-dianisidine Staining
Staining with o-dianisidine was carried out as described [43].
Control and MO-injected embryos at 48 and 72 hpf were
manually dechorionated and fixed with 4% paraformaldehyde
overnight. Fixed embryos were washed three times in PBS and
then incubated in the staining buffer (0.6 mg/ml o-dianisidine,
10 mM sodium acetate (pH 5.2), 0.65% hydrogen peroxide, and
40% ethanol) for 15 min in the dark. Stained embryos were
cleared and stored in benzyl benzoate/benzyl alcohol (2:1, vol/
vol).
Flow Cytometry
Control- and morpholino-injected Tg(gata1:dsRed) embryos
(150 embryos each) were dechorionated manually at 48 hpf, rinsed
for 15 min in calcium-free Ringer’s solution and passed five times
through a 200 ml pipette tip to remove the yolk. The embryos were
dissociated in 0.25% trypsin and 1 mM EDTA for 60 minutes at
28.5uC, during which the sample was passed six times through a
200 ml pipette tip every 10 minutes in order to obtain a single cell
suspension. The dissociated cell suspension was centrifuged at
1000 g for 9 min at 4uC, the supernatant discarded, and the cells
resuspended in ice cold 0.96PBS plus 5% fetal bovine serum and
passed by gravity through a 40 mm nylon mesh filter. Flow
cytometry was performed on a BD LSII instrument (BD
Biosciences). We used wild type zebrafish embryos as a negative
control.
Results
Expression Pattern of hoxd4a
The expression of hoxd4a during zebrafish development was
examined by WISH. Maternal transcripts were seen at the 1 cell
stage, and zygotic transcripts were readily detected from 3 hpf to
48 hpf (Fig. 1A–G,I,L) and in a majority of cells until at least
75% epiboly (8–9 hpf) (Fig. 1D). An anterior expression border in
neurectoderm is visible by 10 hpf (bud stage; data not shown) with
further resolution of the border between rhombomeres 6 and 7
(r6/7) by 12 hpf (Fig. 1E). As observed previously [44,45], at 26–
28 hpf hoxd4a is expressed in the hindbrain with an anterior border
at r6/7, in neural crest migrating to the future branchial arches,
and in the pectoral fin fields (Fig. 1F). We also observed hoxd4a
transcripts in the PBI (Fig. 1I). At no point were hoxd4a transcripts
detected in the PLM or ICM of control embryos. By 48 hpf,
hoxd4a expression was apparent in the AGM and in patches in the
area of the caudal vein plexus (Fig. 1L).
hoxd4a Morphants Exhibit a Defect in Primitive
Hematopoiesis
To understand the function of hoxd4a during zebrafish
embryogenesis, we used two splice-blocking antisense MOs against
either the hoxd4a splice donor or splice acceptor flanking the single
intron interrupting the coding region. Both MOs provoked highly
similar phenotypes and the results obtained with the splice-
acceptor blocker are reported below. Injection of hoxd4a MO
(8 ng) at the 1–4 cell stage resulted in severely deformed embryos
that died by 7 dpf. However, at a reduced dosage of MO (4 ng),
embryos exhibited grossly normal morphology up to 30 hpf but
with a developmental delay of approximately 9 h. In all
experiments reported below, we compared morphants and control
embryos at equivalent developmental stages. In embryos of at least
26 hpf, we routinely assessed the length between the eye and the
otic vesicle as suggested previously [40], as well as the size of the
eye field. In some cases, we also counted somites.
Following injection of the anti-hoxd4a MO, in situ hybridization
revealed a marked reduction of hoxd4a transcripts at 26–28 hpf
(.26 somites) (Fig. 1G–H and I–J) confirmed by qRT-PCR
(Fig. 1W). In particular, hoxd4a expression in the PBI (Fig. 1I) was
lost in 26 hpf morphants (Fig. 1J). Transcripts for hoxd4a likewise
failed to appear in the AGM and caudal vein plexus in 48 hpf
morphants (Fig. 1L–M). Co-injection of capped hoxd4a mRNA
rescued expression in all tissues (Fig. 1K,N). By contrast, the
expression of pax2.1 (a marker for intermediate mesoderm, Fig.
S1A–C vs B–D in File S1), nkx2.5 (a marker for cardiac
mesoderm, Fig. S1E–F in File S1) and myod (a marker of paraxial
mesoderm, Fig. S1G–H in File S1) was unaltered in the
morphants, demonstrating that there was no gross defect in the
overall patterning of the mesoderm.
The onset of blood circulation in zebrafish is at 25 to 26 hpf. In
control-injected embryos at 48 hpf, red blood cells (RBCs)
streamed normally over the yolk, through the ducts of Cuvier
toward the heart, and through the dorsal aorta, posterior cardinal
vein and caudal plexus. By contrast, in hoxd4a morphants the
number of circulating RBCs was considerably reduced (n=96/
100) (Videos S1, S2, S3), but was strongly rescued by co-
injection with capped mRNA for hoxd4a (Video S2). Reduced
RBC production at 48 hph (Fig. 1O–P) and 72 hpf (Fig. 1Q–T)
was confirmed by staining for hemoglobin with o-dianisidine.
RBC production was strongly rescued by co-injection with capped
hoxd4a mRNA (Fig. 1S,T). O-dianisidine staining also revealed
pooling of blood in the head and trunk in some embryos (Fig.
S1I–J in File S1; Video S3) suggestive of vascular defects. A lack
of RBCs was also apparent by observation of the heart (Fig. S1K–
L in File S1). Apart from anemia, pericardial edema and areas of
edema over the yolk sac were also observed from 36 hpf (Fig.
S1M–O in File S1). In addition, the heart rate was also mildly
but significantly slower in morphants at 26–28 hpf and 48 hpf
(Fig. S1P in File S1), and may have affected definitive
hematopoiesis (see Discussion).
As an independent assessment of the extent of erythropoiesis
in hoxd4a morphants, we made use of the Tg(gata1:dsRed)
transgenic line [38] in which the gata1 promoter drives
expression of the Discosoma red fluorescent protein (dsRed) in
hoxd4a in Hematopoiesis and Vasculogenesis
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erythrocytic lineages during primitive and definitive hematopoi-
esis. While a strong signal was observed in the ICM and PBI of
control embryos at 26 hpf, little could be detected in hoxd4a
morphants (Fig. 1U,V) suggesting a deficit of erythrocytic
progenitors during primitive hematopoiesis. To quantify the
apparent reduction of erythrocyte numbers, we performed flow
cytometry on cells isolated from Tg(gata1:dsRed) controls and
morphants at 48 hpf. The results show that morphants have
only 12% as many dsRed-positive cells as controls (Fig. 1X).
Together, these findings support a marked failure of primitive
hematopoiesis following hoxd4a knockdown.
To assess the effect of reduced hoxd4a function on the genetic
programme directing erythroid development, expression of the
erythroid lineage-specific markers gata1 and b embryonic globin 1
(hbbe1) was analyzed by WISH. Both gata1 and hbbe1 transcripts
were diminished in the posterior PLM at 13 hpf (, 8 somites)
(Fig. 2A–B vs C–D) and the ICM and PBI at 26–28 hpf (Fig.
S2A–B vs C–D in File S1), establishing a defect in primitive
hematopoiesis. Co-injection of capped hoxd4a mRNA along with
the hoxd4a MO significantly rescued the expression of both
erythroid markers (Fig. 2E–F; Fig. S2E–F in File S1),
specifically implicating hoxd4a in the phenotype.
Loss of hoxd4a Impairs Definitive Hematopoiesis
Between 26 to 30 hpf, definitive hematopoiesis originates at the
ventral wall of the DA, with expression of runx1 and cmyb marking
the HSCs [1,3]. The expression of runx1 and cmyb in hoxd4a
morphants at 26–28 hpf (Fig. 3A–B vs C-D) and 48 hpf
(Fig. 3E–F vs G-H) was severely down-regulated. The expression
levels of markers of primitive and definitive hematopoiesis were
quantitated by qRT-PCR and showed a strong reduction in hoxd4a
morphants and significant rescue upon co-injection with capped
hoxd4a mRNA (Fig. 3I). Thus, the knockdown of hoxd4a results in
the impairment of both primitive and definitive hematopoietic
lineages.
Knockdown of hoxd4a Disrupts Endothelial Development
In addition to reduced numbers of blood cells, hoxd4a
morphants appeared to lack a normal vasculature. At 48 hpf,
blood cells circulated normally in the axial vessels and tail region
in control embryos, whereas in hoxd4a morphants, little or no
blood flow could be observed or was highly irregular with RBCs
appearing to become blocked in their path through the ISVs.
Blood flow was strongly rescued by co-injection with capped
hoxd4a mRNA (Video S2).
The state of the vasculature in hoxd4a morphants was
investigated through the use of the fli1:EGFP transgenic line
which expresses enhanced GFP under the control of the fli1
locus in endothelial cells [37]. While control embryos at 72 hpf
exhibited normal vascular phenotypes with the formation of
primary ISV joining the dorsal longitudinal anastomotic vessel
(DLAV) (Fig. 4A–B), their morphant counterparts displayed
severely impaired sprouting of ISV precursors and greatly
weakened GFP signal from the region of the presumptive DA
(Fig. 4C–D). In approximately a fifth of morphant embryos,
Figure 1. Expression pattern of hoxd4a and phenotype of hoxd4a morphants. (A–D) Detection of hoxd4a transcripts in early zebrafish
embryos. Animal pole is to the top. (A) 1 cell. (B) 3 hpf. (C) 50% epiboly. (D) 75% epiboly. (E) Dorsal view of flat-mounted embryo at 12 hpf (5–6
somites) doubly stained for expression of hoxd4a and krox20a. The arrow indicates the anterior expression border of hoxd4a, while asterisks denote
expression of krox20a in r3 and r5. Anterior is to the left. The rostral-most portion of the embryo is not captured in the image. (F) Dorsal view of a flat-
mounted embryo at 26–28 hpf (.26 somites) showing hoxd4a expression in hindbrain, branchial arches (white arrowhead, left side only) and
pectoral fin field (black arrowhead, right side only). The white arrow marks the hoxd4a anterior expression border in the hindbrain at the boundary
between r6 and r7. Asterisks denote krox20a expression in r3 and r5. (G–H) Lateral views of 26–28 hpf embryos showing hoxd4a expression in the
central nervous system (arrows) of control embryos (G) and reduced expression in hoxd4a morphants (H). (I–K) hoxd4a expression in the caudal half at
26–28 hpf as shown in lateral views, anterior to the left. hoxd4a expression seen in the PBI of control embryos (I, white arrow) is greatly reduced in
hoxd4a morphants (J). Expression is rescued following co-injection with capped hoxd4a mRNA (K). (L–N) Results of In situ hybridization for hoxd4a at
48 hpf showing expression in the AGM and caudal vein plexus (site of future CHT) of control injected embryos (L, black arrows), greatly reduced
expression in hoxd4a morphants (M), and rescued expression in embryos simultaneously injected with capped mRNA for hoxd4a (N). (O–T)
Hemoglobin within RBCs revealed by o-dianisidine staining. Ventral views at 48 hpf (O,P) and 72 hpf (Q,R) show greatly reduced levels of hemoglobin
in the ducts of Cuvier in hoxd4a morphants (P and R) vs controls (O and Q). Co-injection with capped mRNA for hoxd4a results in rescued RBC
production (S). (T) O-dianisidine staining of the caudal half of a control larva (upper panel) and hoxd4a morphant (middle panel) showing overall
reduction in hemoglobin levels at 72 hpf in morphants, and rescue by co-injection of capped hoxd4a mRNA (lower panel). (U,V) Lateral views of trunk
regions of Tg(gata1:dsRed) embryos at 26 hpf, anterior to the left. The expression of dsRed within proerythroblasts is readily detected in the ICM
(arrow) and PBI (arrowhead) of control-injected embryos (U) but not hoxd4a morphants (V). Scale bars = 100 mm. Ratios indicate the number of
embryos showing the presented phenotype. (W) qRT-PCR shows an overall 3-fold reduction of hoxd4a expression in morphants at 26–28 hpf. Error
bars = standard error. p = 0.02. (X) Quantitation by flow cytometry of dsRed-positive cells in Tg(gata1:dsRed) embryos at 48 hpf showing that
morphants display an 88% reduction in RBCs relative to control-injected embryos. Error bars = standard deviation. p,0.0002.
doi:10.1371/journal.pone.0058857.g001
Figure 2. hoxd4a knockdown disrupts primitive hematopoiesis
and is highly specific. In situ hybridization revealing expression at
13 hpf of erythroid lineage markers gata1 (A,C,E) and b embryonic
globin 1 (hbbe1) (B,D,F). (A,B) Normal expression of gata1 and hbbe1 in
the LPM. (C,D) Expression of gata1 and hbbe1 is strongly down-
regulated in hoxd4a morphants, but rescued by co-injection of capped
mRNA for hoxd4a (E,F). All embryos have been flat-mounted and are
shown in dorsal view. Anterior is to the left. Ratios in the bottom left
corner of all panels indicate the number of embryos showing the
presented phenotype. ctrl, embryos injected with a non-specific
morpholino. MO, embryos injected with the anti-hoxd4a morpholino.
hoxd4a mRNA, embryos simultaneously injected with the anti-hoxd4a
MO plus capped mRNA for hoxd4a. Scale bars equal 100 mm. All images
are at the same magnification.
doi:10.1371/journal.pone.0058857.g002
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the caudal vein plexus was replaced by an amorphous mass of
endothelial tissue (Fig. 4E–F), while anterior bifurcation of the
presumptive aortic vessel could not be observed in others (data
not shown).
The effects of hoxd4a knockdown on vasculogenesis and
angiogenesis were also assessed by exploiting the high endog-
enous levels of alkaline phosphatase characteristic of endothelial
cells. In control embryos, intense signals revealed well-formed
Figure 3. hoxd4a expression is required for transient and definitive hematopoiesis. In situ hybridization on 28 hpf (A–D) and 48 hpf (E–H)
embryos showing expression of runx1 (A,C,E,G) and cmyb (B,D,F,H) in presumptive HSCs arising in the PBI (arrows in A and B) and AGM (arrows in E
and F). Expression of both genes was severely reduced in hoxd4a morphants (C,D and G,H). Ratios in the bottom right corner of images indicate the
fraction of embryos showing the presented phenotype. ctrl, embryos injected with a non-specific morpholino. MO, embryos injected with the anti-
hoxd4a morpholino. hoxd4a mRNA, embryos simultaneously injected with the anti-hoxd4a MO plus capped mRNA for hoxd4a. Scale bars equal
100 mm. All images are at the same magnification. (I) qRT-PCR confirms the strong depletion of hematopoietic gene expression in hoxd4a morphants
at 26–28 hpf, and restored expression following co-injection with capped mRNA for hoxd4a. Samples were normalized to b-actin. Error bars indicate
standard error. By comparison to controls and rescuants, the gene expression levels of all morphants were statistically different to p#0.02 except for
gata1 control vs morphant (p = 0.04) and hbbe1 rescuant vs morphant (p = 0.09).
doi:10.1371/journal.pone.0058857.g003
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ISV, subintestinal vessels (SIVs) and vertebral artery (VTA),
whereas such vessels were indiscernible or highly reduced in
hoxd4a morphants (Fig. 4G–H). Co-injection with hoxd4a
mRNA yielded a marked rescue of ISV, SIV and VTA
(Fig. 4I). The pooling of blood that we observed might be
attributable to hemorrhaging resulting from these defects in
vascular development (Fig. S1I–J in File S1; Video S3).
Similar hemorrhaging has been observed in fli1 morphants [46].
Together, our results confirm profound defects in vasculo- and
angiogenic processes in hoxd4a morphants.
To evaluate the effect of hoxd4a knockdown on genetic programs
directing vasculogenesis and angiogenesis, we performed in situ
hybridization for the endothelial markers fli1 and flk1. Both genes
were significantly reduced in the LPM of hoxd4a morphants at
13 hpf (Fig. 5A–B vs C–D), and in the major trunk vessels and
ISVs at 26 hpf (Fig. S3A–B vs C–D in File S1), implying that
Figure 4. Loss of hoxd4a function impairs development of the vasculature. (A–D) Fluorescent images of the trunk and tail regions of
Tg(fli1:EGFP) embryos at 48 hpf. The panels present merged bright field and fluorescent images (A,C) or fluorescent images only (B,D) The normal
pattern of the vasculature (A,B) is severely disrupted in hoxd4a morphants (C,D) Dorsal extremities of ISV sprouts that fail to contact the DLAV are
marked by white dots (D). The caudal vein plexus of control embryos (E, arrowheads) is replaced by a disorganized mass of endothelial tissue in
hoxd4a morphants (F, arrowheads). (G–I) Alkaline phosphatase staining at 72 hpf revealing the vasculature in (G) control-injected larvae, (H) hoxd4a
morphants, and (I) rescued larvae co-injected with capped mRNA for hoxd4a. Dorsal aorta (DA), posterior cardinal vein (PCV), inter-segmental vessels
(ISV), caudal artery (CA), dorsal longitudinal anastomotic vessel (DLAV), caudal vein (CV) and vertebral artery (VTA). All images show lateral views, with
anterior to the left and dorsal on top. Scale bars equal 100 mm.
doi:10.1371/journal.pone.0058857.g004
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hoxd4a morphants are defective in axial vasculature. Co-injection
of capped mRNA for hoxd4a, rescued both fli1 and flk1 expression,
establishing a specific role for hoxd4a in the altered gene expression
pattern (Fig. 5E–F; Fig. S3E–F in File S1).
Early in development, a common primary blood vessel forms
at the midline, partly under the influence of VEGF secreted by
ventral somitic tissue. The DA and PCV derive from this
common primary vessel through a process of ventral sprouting
dependent on efnb2a and ephb4a [2]. We observed an amorphous
mass of tissue in the region of the caudal vein plexus at 48 hpf
(Fig. 4F), a site of hoxd4a expression (Fig. 1H) and a failure of
anterior aortic bifurcation (data not shown), suggesting defects
in primary vessel formation. We therefore assessed the
expression of vegf, the arterial marker efnb2a and the venous
marker ephb4a. At 13 hpf, the expression of efnb2a and vegf was
significantly reduced in the morphants, implicating defective
Figure 5. Knockdown of hoxd4a disrupts the endothelial programme in zebrafish embryos. In situ hybridization at 13 hpf revealing
expression of pan-endothelial markers fli1 and flk1 in control-injected embryos (A,B), hoxd4a morphants (C,D), and rescued embryos co-injected with
anti-hoxd4a MO and capped mRNA for hoxd4a (E,F). (G,I) Expression of the marker of arterial identity efnb2a in controls (G) and hoxd4a morphants (I).
(H,J) Expression of the endothelial inducer vegf in controls (H) and hoxd4a morphants (J). (K,L) Expression of the venous marker ephb4a in controls (K)
and hoxd4a morphants (L). Ratios indicate the fraction of embryos showing the presented phenotype. All images show dorsal views with anterior to
the left except H, J, K and L which are lateral views with anterior to the left. Scale bars equal 100 mm. (M) qRT-PCR results showing depletion at 26–
28 hpf of angioblast and vascular gene expression in hoxd4a morphants and rescue by co-injection of capped mRNA for hoxd4a. Samples were
normalized to b-actin. Error bars indicate standard error. By comparison to controls and rescuants, the gene expression levels of all morphants were
statistically different to p#0.02 except for lmo2 control vs morphant (p = 0.04) and lmo2 rescuant vs morphant (p = 0.05).
doi:10.1371/journal.pone.0058857.g005
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artery specification (Fig. 5G–H vs I–J). Likewise, the expres-
sion of the vein marker ephb4a was reduced at 13 hpf (Fig. 5K–
L). The expression of efnb2a remained attenuated at 26–28 hpf,
but that of ephb4a had recovered (Fig. S3 G–J in File S1).
Results for fli1, flk1, vegf and efnb2a were quantified by qRT-
PCR on RNA extracted from 26–28 hpf embryos. The results
confirm the decreased expression of these genes in hoxd4a
morphants, and the ability of co-injected mRNA for hoxd4a to
rescue their expression (Fig. 5M).
A Role for hoxd4a in Hemangioblast Formation through
Regulation of meis1.1
The hemangioblast is the common precursor to the blood and
endothelial lineages and is defined by early expression of such
genes as fli1, scl1 and lmo2 in both the ALM and PLM, and gata5 in
the ALM only [1,3,46,47]. The severe defects in both blood and
endothelial lineages in hoxd4a morphants suggested that the
hemangioblast itself may be compromised. To assess this idea,
the expression of hemangioblast markers scl1 and lmo2 was
analyzed by in situ hybridization. Significant down-regulation of
both genes was observed in morphants at 13 hpf (Fig. 6A–B vs
C–D). The impaired expression of scl and lmo2 persisted at 26 hpf
(Fig. S4A–B vs C–D in File S1), suggesting that their later
independent functions in definitive hematopoiesis were also
compromised. Co-injection of capped hoxd4a mRNA rescued scl
and lmo2 expression at 13 hpf (Fig. 6E–F) and 26 hpf (Fig. S4E–
F in File S1).
To establish the hierarchy between these key regulators, the
hoxd4a MO was co-injected with capped mRNA for either scl or
fli1. The expression of scl and lmo2 was rescued in both cases
(Fig. 7A–B vs C-D; Fig. S5A–B vs C–D in File S1), placing the
action of hoxd4a above these early acting effectors of hemangioblast
specification [3,46].
Consistent with the above findings, expression of gata1 and hbbe1
at 13 and 26 hpf was rescued by co-injection of scl and fli1 mRNA
(Fig. 7E–H; Fig. S5E–H in File S1), though rescue by fli1 at
13 hpf was incomplete. Expression of the vasculogenic markers fli1
and flk1 was likewise rescued by scl and fli1 mRNA at 13 hpf
(Fig. 7I–L) and 26 hpf (Fig. S5I–L in File S1). Together, these
results reveal that hoxd4a occupies a very high position in the
transcriptional hierarchy governing hemangioblast formation or
function.
A number of studies have demonstrated major regulatory roles
for Hox transcription factors in hematopoietic cell fate decisions
[11–13,22]. HOX proteins interact with other DNA-binding
cofactors including TALE homeoproteins of the MEIS and PBX
families, and Meis homologs have been implicated in the earliest
stages of hematopoiesis and vasculogenesis in mice and zebrafish
[18–20]. We therefore examined the expression of meis1.1 in
hoxd4a morphants.
At 13 hpf, meis1.1 expression was significantly reduced in the
PLM of hoxd4a morphants (Fig. S6E–F in File S1), while at 26–
28 hpf meis1.1 expression was reduced throughout the embryo
(Fig. 8A–B and below) and could be rescued with capped hoxd4a
transcripts (Fig. 8C). These results strongly suggested that one of
the primary causes of hematopoietic and vasculogenic defects in
hoxd4a morphants may be the loss of meis1.1 function. To test this
notion, we attempted to rescue the expression of the genetic
markers of hemangioblast formation, primitive hematopoiesis and
vasculogenesis (scl, gata1 and fli1) in hoxd4a morphants by co-
injection with mRNA for meis1.1. All three markers were strongly
rescued at 13 hpf (Fig. 8D–L). Likewise, restoration of meis1.1
rescued the normal development of the vasculature including the
DA, ISV, DALV and SIV as revealed in fli1:EGFP transgenics
(Fig. 8M) and following visualization of the vasculature with
alkaline phosphatase (Fig. 8N). The circulation is also largely
restored in these embryos, especially robust in the DA, though less
evident in the return flow through the caudal vein plexus and PCV
(Video S4).
Figure 6. hoxd4a is required for hemangioblast formation. (A,B)
Normal expression at 13 hpf of posterior hemangioblast markers scl1
(A) and lmo2 (B) in the PLM. (C,D) Expression of these markers is greatly
reduced in hoxd4a morphants, but is rescued by co-injection of capped
mRNA for hoxd4a (E,F). Ratios indicate the fraction of embryos showing
the presented phenotype. Anterior is to the left. A, C and E are dorsal
views of flat-mounted specimens while B, D and F are lateral views.
Scale bars equal 100 mm. A is at a lower magnification than C and E.
doi:10.1371/journal.pone.0058857.g006
Figure 7. scl1 and lmo2 act downstream of hoxd4a to direct
formation of the hemangioblast. All images are of hoxd4a
morphants at 13 hpf. In situ hybridization was performed to detect
expression of scl1 and lmo2 (A–D), gata1 and hbbe1 (E–H) and fli1 and
flk1 (I–L). To test for rescue of gene expression, embryos were co-
injected with capped mRNA for either scl1 or fli1 as indicated on the left.
Ratios indicate the fraction of embryos showing the presented
phenotype. Scale bars equal 100 mm.
doi:10.1371/journal.pone.0058857.g007
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Along with cloche [7], the cdx1 and cdx4 genes are among the
earliest effectors of the hemangioblast lineage [9,10]. Doubly
deficient cdx1/cdx4 embryos lack midline vasculature and show a
complete failure of hematopoiesis [9]. In hoxd4a morphants, cdx4
expression is unaltered at 13 hpf (Fig. S6A–B in File S1) and
26 hpf (Fig. S7Q–R in File S1). Moreover, injection of capped
cdx4 mRNA fails to rescue defects of hematopoiesis or the
vasculature in hoxd4a morphants (data not shown). We conclude
that hoxd4a acts downstream or parallel to cdx1/cdx4 but upstream
or parallel to meis1.1.
We then asked whether cdx4, hoxd4a and meis1.1 are ever
temporally and spatially co-expressed so as to directly implement
this hierarchy in a cell-autonomous fashion. Prior fate-mapping
studies have established that precursors to the PLM hemangio-
blasts arise from the ventral-most presumptive mesoderm of shield-
stage embryos [5,35,36], a tissue in which hoxd4a is expressed
(Fig. 1C). In situ hybridization on shield-stage embryos showed
strong overlapping expression of cdx4, hoxd4a and meis1.1 in
ventral-most mesoderm (Fig. 9A,C,F). Importantly, knockdown
of hoxd4a provoked a reduction in hoxd4a and meis1.1 expression in
this same tissue (Fig. 9D,G). By contrast, cdx4 expression was
unaffected (Fig. 9B). Importantly, co-injection of hoxd4a mRNA
restored hoxd4a transcript levels and rescued the expression of
meis1.1 (Fig. 9E,H). qRT-PCR on mRNA from controls, hoxd4a
morphants and rescuants at the shield-stage validated results from
in situ hybridization (Fig. 9I). The co-expression of hoxd4a with
cdx4 and meis1.1 in tissue fated to give rise to PLM hemangioblasts,
and the control of meis1.1 expression by hoxd4a in this same tissue,
strongly suggests that the failure to form PLM hemangioblasts in
hoxd4a morphants is due to defects initiated at the shield stage.
Members of the MEIS family regulate Hox gene expression in
both invertebrates and vertebrates [14,48,49]. Both gene families
have likewise been implicated in hematopoietic and angiogenic
processes [13,18–20,22]. We therefore wished to determine
whether knockdown of hoxd4a and subsequent reduction in meis1.1
function might have provoked Hox gene deregulation. We
assessed the expression of multiple Hox genes following hoxd4a
knockdown at 26–28 hpf by quantitative RT-PCR (Fig. 10A).
More than half of the Hox genes tested showed significant down-
regulation, including hoxb4a, hoxb6b, hoxb7a and hoxa9a, all of which
have been strongly implicated in hematopoietic processes.
Likewise, hoxd3a, whose ortholog has been shown to promote
angiogenesis in the mouse [50,51], was also down-regulated.
Consistent with results from in situ hybridization, cdx4 expression
was unaffected. In situ hybridization on a number of these Hox
genes confirmed decreased expression at 13 and 26–28 hpf (Fig.
S7 in File S1). These results validate the suggestion that the early
loss of meis1.1 function leads to the deregulation of several, though
not all, Hox genes, thereby providing a fuller explanation for how
the initial impairment of a single Hox gene, hoxd4a, can lead to
massive defects in hematopoiesis, vasculogenesis, and angiogenesis.
Discussion
This study places hoxd4a near the top of a regulatory cascade
directing hematopoiesis, vasculogenesis and angiogenesis in
zebrafish embryos (Fig. 10B). This unexpected role of hoxd4a is
at least partly due to its positive regulation of meis1.1, and is likely
to have both direct and indirect consequences. Most directly,
decreased hoxd4a function leads to reduced expression of meis1.1 in
the ventral-most presumptive mesoderm of the shield-stage
embryo, a tissue fated to produce the hemangioblast in addition
to unipotential erythrocytic and endothelial progenitors [5,35,36].
A few hours later, hemangioblast markers are severely reduced in
the PLM, leading us to propose that hoxd4a and meis1.1 loss of
function at the shield stage interferes with the specification of
hemangioblasts and unipotential progenitors. Less directly, hoxd4a
knockdown leads to massive deregulation of Hox gene expression,
including a number of Hox genes previously implicated in these
processes such as hoxb4a, hoxb6b, hoxb7a and hoxa9a [9,10].
In support of this model, injection of capped mRNA for either
hoxd4a or meis1.1 rescues essentially all aspects of the knockdown
phenotype. It is likely that much of the effect of the loss of meis1.1
expression follows from the impaired function of MEIS-PBX and
MEIS-PBX-HOX transcriptional complexes [14,20,52], though
functions of MEIS that are independent of HOX or PBX should
also be affected.
Three reports describe the effects of meis1.1 loss of function on
hematopoiesis and vasculogenesis in zebrafish embryos [18–20].
Only Ouwehand and co-workers [18] observed, as we do, defects
in both processes. Suzuki and co-workers [19] observed defects in
the vasculature, heart edema and weakened heartbeat resulting
from decreased meis1.1 function, and implicated a downstream
impairment in flk1 and vegf expression, consistent with our findings.
Waskiewicz and co-workers [20] found that loss of meis1.1 function
caused severe defects in erythropoiesis, but did not observe
vasculature defects nor detect alterations in either flk1 or Hox
expression. Together, these results suggest that the complement of
defects we observe in this study are likely to exceed what can be
explained by a simple loss of meis1.1 function. A full account of the
phenotypes reported here will likely have to consider the roles of
meis1.1, hoxd4a itself, and the downstream effects on the expression
of multiple Hox genes.
Figure 8. meis1.1 is down regulated in hoxd4a morphants and
meis1.1 mRNA rescues hematopoietic and vasculogenic gene
expression in hoxd4a morphants. Expression of meis1.1 in control
(A), morphant (B) and hoxd4a-rescuant (C) embryos at 26–28 hpf. (D–I)
At 13 hpf, normal expression of gata1, scl1 and fli1 (D–F) is reduced in
hoxd4a morphants (G–I), but rescued upon co-injection with capped
mRNA for meis1.1 (J–L). (M,N) Rescue of vascular patterning in hoxd4a
morphants by co-injection with capped mRNA for meis1.1 as visualized
in Tg(fli1:EGFP) transgenics at 48 hpf (M) and by alkaline phosphatase
staining at 72 hpf (N). Scale bars equal 100 mm.
doi:10.1371/journal.pone.0058857.g008
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The phenotype we report here is in some ways closer to that
reported for cdx1 plus cdx4 double loss-of-function embryos,
including severe hematopoietic (both primitive and definitive) and
vasculogenic defects, and impaired expression of multiple Hox
genes [9,10]. By contrast, Hox gene expression is not affected in
meis1.1 or meis3 morphants [20,53]. However, we do not observe
significant changes in cdx4 expression in hoxd4a morphants, and the
hoxd4a morphant phenotype cannot be rescued by the injection of
capped mRNA for cdx4. It may be that hoxd4a is an immediate
downstream effector of cdx1/4 function. Alternatively, hoxd4a may
act in parallel with cdx1 and cdx4 such that their function, but not
expression, is compromised. Such a mechanism is implied by
Figure 9. Expression of meis1.1, but not cdx4, is impaired in hoxd4amorphants at the shield stage. Expression of cdx4 (A,B), hoxd4a (C–E)
and meis1.1 (F–H) in control (A,C,F), hoxd4a morphants (B,D,G) and rescuants injected with hoxd4a mRNA (E,H) observed at the shield stage. Asterisks
denote the ventral-most mesoderm fated to give rise to hemangioblast in addition to unipotential hematopoietic and angiogenic progenitors. Ratios
indicate the fraction of embryos showing the presented phenotype. Scale bars equal 100 mm. (I) qRT-PCR was used to quantitate relative mRNA levels
in controls, morphants and rescuants as indicated. Error bars present the standard error. Decreased expression of hoxd4a and meis1.1 in hoxd4a
morphants is significantly lower than both controls and rescuants to p#0.02.
doi:10.1371/journal.pone.0058857.g009
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recent studies showing that products of murine CDX1 and
HOXD4 form functional heterodimers [54]. A direct role for cdx1
and cdx4 in definitive hematopoiesis could not be established with
certainty due to major effects in the development of the dorsal
aorta in doubly deficient embryos [9]. By contrast, hoxd4a
morphants do form distinctly separate DA and PCV, and these
vessels are open to circulation. Nonetheless, we did observe
impaired expression of the arterial marker efnb2a, suggesting that
the DA may not be appropriately specified in hoxd4a morphants,
an event that could lead to defective HSC formation. The mildly
reduced heart rate of morphants may contribute to decreased
efnb2a expression and impaired specification of HSCs due to sub-
optimal levels of nitrous oxide (NO) signaling [55]. This raises the
possibility that the observed impairment of definitive hematopoi-
esis is a secondary event, and we are therefore cautious in
assigning a direct role for hoxd4a and meis1.1 in this process.
Nonetheless, depressed NO signaling cannot explain all of the
defects noted here, since the reduced flk1 expression that we
observe at 13 and 26 hpf is not an expected consequence of
decreased heart rate [56,57]. In addition, hoxd4a morphants show
Figure 10. cdx4, meis1.1 and Hox gene expression in hoxd4amorphants, and a genetic pathway for specification of hemangioblasts
and unipotential stem cells. (A) qRT-PCR showing decreased expression of meis1.1 and many, but not all, hox genes in hoxd4a morphants at 26–
28 hpf. By contrast, cdx4 levels are unchanged. Samples were normalized to b-actin. Error bars indicate standard error. All pairs marked with an
asterisk meet statistical significance (p#0.02). (B) Based on the results presented here and those in the literature, we propose a pathway in which
hoxd4a andmeis1.1 occupy sequential steps downstream of cloche and cdx1/4 in a genetic programme leading to the specification of hemangioblasts
and unipotential angiogenic and hematopoietic stem cells. The effects of hoxd4a knockdown may be magnified through positive cross-regulatory
interactions withmeis1.1. The observed effects on the expression of multiple Hox genes could be due to the direct action of hoxd4a and meis1.1. Non-
exclusively, cdx1 and cdx4 may act in conjunction with hoxd4a and meis1.1 in a feed-forward type of mechanism to regulate one or more of these
same Hox genes with widespread consequences for vasculogenesis, angiogenesis and hematopoiesis at all levels.
doi:10.1371/journal.pone.0058857.g010
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reduced efnb2a expression in tissues that should not be affected by
NO levels consistent with a direct role for hoxd4a or meis1.1 and
similar observations in meis1.1 morphants [18,19].
Some of the phenotypic defects observed here can be explained
by effects on relatively early embryonic events, such as impaired
formation and function of hemangioblast precursors, as indicated
by the loss of hemangioblast markers scl, lmo2 and fli1, and the
ability of the capped mRNAs for these genes to rescue
development. However, other aspects of the phenotype may
represent later and considerably more downstream functions. For
example, decreased expression of efnb2a points to a defect in
arterial specification downstream of hemangioblast formation and
function, as has been noted in meis1.1 morphants [18,19].
Likewise, much of the vasculogenic and angiogenic defects could
be explained by the impairment of the downstream roles of fli1,
vegf and flk1 in these processes. The vegf gene is also known to play
a role in the initiation of hematopoiesis [4], and its downregulation
is therefore likely to contribute to many aspects of the phenotype
reported here.
Expression of gata1 commits hematopoietic precursors to
erythropoiesis during primitive hematopoiesis in the ICM. Later
in development, runx1 and cmyb are required for myeloid
development during definitive hematopoiesis in the equivalent of
the AGM [1,3]. Following hoxd4a knockdown, decreased expres-
sion of scl and lmo2 is likely to contribute to a failure in the
induction of gata1 and defective primitive hematopoiesis as
evidenced by a loss of expression of hbbe1; but loss of scl and
lmo2 function would also account for the observed defect in runx1
and cmyb expression and the subsequent failure of definitive
hematopoiesis. Interestingly, we observe the expression of hoxd4a
at 26–28 hpf in the PBI and at 48 hpf in the AGM and caudal
vein plexus. The caudal vein plexus is the site of the future CHT
[4], an early site of definitive hematopoiesis, functionally
equivalent to the fetal liver of mice [4,6]. Thus, hoxd4a might
play a direct role in primitive and definitive hematopoiesis apart
from its indirect role through meis1.1 earlier in development. Both
early and later functions of meis1.1 in hematopoiesis and
vasculogenesis are also likely, given very early effects on the
expression of hemangioblast markers and later expression of
meis1.1 in the ICM as described by others [19,58]. Multiple sites of
action along a pathway leading from hemangioblast specification
to vasculogenesis, angiogenesis and primitive and definitive
hematopoiesis could also help to explain why epistasis experiments
give apparently conflicting results. For example, one report places
meis1.1 downstream of scl for the induction of primitive hemato-
poiesis [18], whereas our own work places meis1.1 upstream of scl
at an earlier time point during hemangioblast specification.
Hox gene expression in vertebrates is implemented in two
phases, an early phase in presumptive mesoderm around
gastrulation and a late phase in the body proper [59–65]. During
gastrulation in Xenopus, timed interactions between the organizer
and non-organizer mesoderm induce Hox expression and pattern
the AP axis [59], while impaired Hox gene expression can alter the
timing of ingression through the primitive streak in the gastrulating
chick [65]. Although the widespread deregulation of late-phase
Hox gene expression seen after hoxd4a knockdown could be
attributed to defects in gastrulation, two observations argue against
this. First, not all the Hox genes we tested were affected, an
observation inconsistent with a global gastrulation defect. Second,
our demonstration that the expression of markers of paraxial
mesoderm (myod), cardiac mesoderm (nkx2.5) and intermediate
mesoderm (pax2.1) was unaffected does not support a major
impairment of gastrulation movements. Nonetheless, our findings
emphasize the importance of Hox gene function in the early peri-
gastrulation phase [61–65].
Mice lacking Hoxd4 function are viable and fertile, and display
defects of the anterior vertebral skeleton [33,34]. Although an
extensive analysis of vasculogenesis and hematopoiesis has not
been undertaken in Hoxd4 null mice, their viability suggests that
there is no severe impairment of these processes. By contrast,
mutation of the paralogous Hoxb4 gene does lead to hematopoietic
defects and some loss of viability, though these mice are still able to
complete embryogenesis and many survive to adulthood
[17,34,66–68]. In striking contrast to the mouse, we show here
that loss of hoxd4a function has severely deleterious consequences
for hematopoiesis, vasculogenesis and angiogenesis. We suggest
that this may be due to a dependency of meis1.1 expression on
hoxd4a function that was either acquired by teleosts (or simply
acquired by zebrafish) or lost in mammals. It may also be that
while Hoxb4 has the predominant role in these processes in
mammals, evolution has selected for hoxd4a to take on these
functions in teleosts. This situation may be partly analogous to that
of the midkine orthologs in mice and zebrafish; the two teleost
midkine genes are strongly expressed in the adult brain, whereas the
mouse ortholog is not [69], implying the acquisition or loss of
function in the course of evolution.
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Figure S1 Patterning and morphology in hoxd4a mor-
phants. (A–H) Knockdown of hoxd4a does not perturb overall
patterning of the mesoderm. (A–D) Expression of pax2.1 shows
that intermediate mesoderm forms and matures normally in hoxd4a
morphants at 13 hpf (B) and 26–28 hpf (D) vs controls (A,C). (E,F)
nkx2.5 expression in the precardiac lateral plate mesoderm at
13 hpf is normal in control (E) and morphant embryos (F). (G,H)
myod expression in paraxial mesoderm is normal in control (G) and
morphant embryos (H). Images in C, D, G and H are lateral views
with anterior to the left. A, B, E and F show dorsal views with
anterior to the top (A,B) or left (E,F). (I to O) Lateral views of
control and hoxd4a-MO-injected larvae at 72 hpf. (I,J) Staining of
hemoglobin with o-dianisidine reveals areas of hemorrhage such as
in the head (I, arrowheads) and trunk (J, arrowheads) in some
hoxd4a morphants. (K,L) Control larvae (K) but not hoxd4a
morphants (L) show abundant RBCs passing through the heart
(arrowheads). (M–O) Unlike control larvae (M), hoxd4a morphants
display pericardial edema and edema over the adjacent yolk (N,O,
arrowheads). Scale bars equal 100 mm. (P) The heart rate in
morphants at 26–28 and 48 hpf was mildly reduced, but in a
statistically significant manner as determined by unpaired
Student’s t test (p,0.0001). Error bars give standard deviation.
(TIF)
Figure S2 Reduced expression of markers of primitive
hematopoiesis gata1 and b embryonic globin (hbbe1) in
hoxd4a morphants. WISH in control and morphant embryos
at 26–28 hpf showing the expression of gata1 (A,C,E) and hbbe1
(B,D,F) in the ICM and PBI (white arrowheads). Normal
expression of gata1 and hbbe1 (A,B) is severely reduced in hoxd4a
morphants (C,D) and rescued by co-injection with capped mRNA
for hoxd4a (E,F). All images are lateral views with anterior to the
left. ctrl, embryos injected with a non-specific morpholino. MO,
embryos injected with the anti-hoxd4a morpholino. hoxd4a mRNA,
embryos simultaneously injected with the anti-hoxd4a MO plus
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capped mRNA for hoxd4a. Scale bars equal 100 mm. All images
are at the same magnification.
(TIF)
Figure S3 Reduced expression of markers of angiogen-
esis and venous specification in hoxd4amorphants.WISH
in control and morphant embryos at 26–28 hpf showing the
expression of fli1 (A,C,E) and flk1 (B,D,F). Normal expression of fli1
and flk1 (A,B) is severely reduced in hoxd4a morphants (C,D) and
rescued by co-injection with capped mRNA for hoxd4a (E,F). White
or black dots denote the tips of dorsally sprouting ISVs. Relative to
controls (G,H), the expression of the arterial marker efnb2a is
reduced in morphants at 26–28 hpf (I), while the venous marker
ephb4a in morphants has recovered (J). Scale bars equal 100 mm.
(TIF)
Figure S4 Reduced expression of scl and lmo2 in hoxd4a
morphants at 26–28 hpf. (A–J) Expression analysis of scl (A,C,E)
and lmo2 (B,D,F) at 26–28 hpf. Normal expression of scl and lmo2
(A,B) is severely reduced in hoxd4a morphants (C,D) and rescued by
co-injection with capped mRNA for hoxd4a (E,F) All images present
lateral views with anterior to the left and dorsal on top. Scale bars
equal 100 mm. All images are at the same magnification.
(TIF)
Figure S5 scl1 and fli1 act downstream of hoxd4a to
direct formation of the hemangioblast. All images are of
hoxd4a morphants at 26–28 hpf previously injected with capped
mRNAs for either scl1 or fli1 as indicated on the left. WISH was
performed to detect expression of scl1 and lmo2 (A–D), gata1 and
hbbe1 (E–H) and fli1 and flk1 (I–L). Scale bars equal 100 mm. All
images are at the same magnification.
(TIF)
Figure S6 Knockdown of hoxd4a results in decreased
expression of meis1.1 but not cdx4 at 13 hpf (,8
somites). (A–F) Expression of cdx4 (A,B), hoxd4a (C,D) and
meis1.1 (E,F) in control (A,C,E) and hoxd4a morphants (B,D,F) at
the shield stage. The white arrowheads in C and D denote the
hoxd4a anterior expression boundary in the hindbrain. Scale bars
equal 100 mm. All images are at the same magnification.
(TIF)
Figure S7 The expression of multiple hox genes is
reduced at 26–28 hpf in hoxd4a morphants. Images are
dorsal views (A–H) and lateral views (I–P) of embryos taken
through in situ hybridization for the indicated hox genes. Relative to
control embryos (A,C,E,G,I,K,M,O), hox gene expression is
reduced in hoxd4a morphants (B,D,F,H,J,L,N,P). All embryos
were simultaneously probed for krox20a expression in r3 and r5 as
in Figure 1C. (Q–R) cdx4 expression is unchanged in control (Q)
and hoxd4a morphants (R) at 26–28 hpf. Scale bars equal 100 mm.
All images are at the same magnification.
(TIF)
Table S1 Primers used for cDNA cloning.
(TIF)
Table S2 Primers for quantitative RT-PCR.
( F)
Video S1 Anterior blood flow in control and hoxd4a
morphant embryos. Lateral view focusing on the anterior half
of a 48 hpf embryo including the region of the heart, future
branchial arches and yolk of control embryos and hoxd4a
morphants. In particular, note robust streaming of blood cells
through the ducts of Cuvier over the yolk in the control, but an
almost complete absence of circulation in the hoxd4a morphant.
(7Z)
Video S2 Trunk blood flow in control, hoxd4amorphant
and rescued embryos. Lateral view of the trunk at 48 hpf in a
control, hoxd4a morphant and rescuant previously injected with
capped mRNA for hoxd4a. Circulation is vigorous in control and
rescuant embryos, with abundant RBCs flowing caudally along the
DA, streaming dorsally through the ISVs, caudally through the
DLAV, and rostrally through the caudal vein and PCV. By
contrast, the number of blood cells is greatly reduced in morphants
and blood cells are unable to transit the truncated ISVs.
(7Z)
Video S3 Tail blood flow in control and hoxd4a
morphant. Lateral view of the tail region in control and hoxd4a
morphant embryos at 48 hpf. Control embryos display vigorous
blood flow through the DA, ISVs, DLAV and caudal vein plexus.
By contrast, morphants show a highly reduced blood cell count
with individual blood cells moving slowly caudally through the DA
and returning sporadically and haltingly through the caudal vein
plexus. Blood cells do not transit from the DA to the DLAV along
the ISVs, unlike control embryos. The reddish appearance of the
tissue in the caudal vein plexus (white arrows) appears to be due to
the accumulation of RBCs.
(7Z)
Video S4 Rescue by meis1.1 mRNA of trunk blood flow
in hoxd4a morphant embryos. Video first showing vigorous
circulation through the blood vessels of a control embryo at
48 hpf, followed by the absence of blood and weak circulation in a
hoxd4a morphant. The last clip demonstrates significant rescue of
blood cell count and vasculature in hoxd4a morphants rescued by
co-injection of meis1.1 mRNA, including the ability of blood cells
to traverse from the DA to the DLAV along intact ISVs.
(7Z)
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